A small molecule in a peptide catalogue
5-Amino-1MQ is a quinolinium compound: a small organic molecule, not a chain of amino acids. It sits in this catalogue because it appears in metabolic research alongside compounds that are peptides, not because it shares their chemistry.
That distinction has practical consequences. Small molecules behave differently in storage, in solution and in how they are handled, and assuming peptide guidance applies to them is a mistake.
If you came here asking what is 5-amino-1MQ, the first correction is that it is not a peptide at all but a small quinolinium molecule that happens to be studied alongside them. Everything practical about handling it follows from that, not from the catalogue it sits in.
Inhibiting an enzyme, not activating a receptor
Almost every other compound in this catalogue works by engaging a receptor. 5-Amino-1MQ does the opposite kind of thing: it is studied as an inhibitor of nicotinamide N-methyltransferase, an enzyme involved in how cells handle nicotinamide.
That enzyme sits near the NAD+ salvage pathway, which is why the compound turns up in the same conversations as the coenzyme research. Whether inhibiting it produces anything useful is exactly what the studies are examining.
Working by inhibiting an enzyme rather than activating a receptor puts it in a small minority here, and it shares the longevity shelf with equally over-summarised compounds such as epitalon. Inhibition also makes the research read differently: what has to be demonstrated is something not happening, which is harder to show cleanly than a signal switching on.
| Type | Small molecule, not a peptide |
| Class | Quinolinium compound |
| Proposed target | NNMT, an enzyme |
| Mechanism type | Inhibition rather than activation |
| Format | Pre-filled research pen |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Cell models and animal work |
| Category | Research use only |
Facts about the substance itself, none of which extend to effects.
Where the evidence currently sits
The work is largely in cell models and animals, examining metabolic markers and adipocyte behaviour. It is a young field and the compound has not been through the kind of development programme that would produce human data.
Read alongside the online summaries, the studies are considerably more cautious. That gap is a recurring feature of newer compounds and it is worth checking for.
How young that literature is becomes obvious the moment you read it directly rather than through a summary, and the record on PubMed is where to do that. One practical warning follows from the chemistry rather than the evidence: because this is not a peptide, the failure modes described on what happens when a peptide degrades do not map onto it directly.
Why the handling rules do not simply carry over
Peptide guidance is built around peptide chemistry: hydrolysis of the bonds between residues, aggregation, oxidation. A small molecule degrades by its own routes, so the freeze-thaw cautions that matter for a reconstituted peptide, set out on the freeze-thaw and stability page, are not automatically the right cautions here.
That is the practical reason we flag its category at the top rather than burying it. Reaching for peptide storage habits and assuming they transfer is a small error that compounds over the life of a sample, and it is entirely avoidable once you know what the material actually is.
5-Amino-1MQ in the catalogue
Purity verified by HPLC at 99% and above; the batch document is yours on request.
Where 5-Amino-1MQ fits in
The three pages that sit closest to this one.
About 5-Amino-1MQ
A few things worth knowing before you buy.